Dr. Lal Path Labs Ltd. has informed the Exchange about Convening of 32nd Annual General Meeting (AGM) of the Company on Saturday, July 25, 2026, through Video Conferencing/ Other Audio-Visual Means (VC/ OAVM).
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 12.8 pts more than Nifty Smallcap 250 and 12.0 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr. Lal PathLabs reported consolidated revenue of INR 27,629 million for FY26, up about 12% from INR 24,614 million in FY25, with profit for the year at INR 5,098 million versus INR 4,922 million. Q4 FY26 revenue grew to INR 7,027 million from INR 6,026 million a year earlier, with quarterly PAT of INR 1,322 million. The Board recommended a final dividend of INR 4 per share, taking total FY26 dividend to INR 20.5 per share (1:1 bonus issue was done in December 2025). The company will acquire 100% of Shahbazkers Diagnostic Centre, set up a wholly owned subsidiary in Dubai (Dr. Lal PathLabs FZCO), and re-appoint the Executive Chairman and an Independent Director for five-year terms. The 32nd AGM is set for July 25, 2026, via video conferencing.
Steady revenue and earnings growth, supported by a strong total dividend payout and clean audit, is positive for shareholders. The acquisition and Dubai expansion signal continued inorganic growth, while the one-time Labour Codes charge of INR 301 million slightly trims headline FY26 profit but does not affect cash flows.